Cytokinetics Inc Insider Trading
Every director, officer and 10% holder of Cytokinetics Inc has to report each trade in its stock within two business days of making it. This is those filings.
CYTK on carbonthat →Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| Fady Ibraham MalikEVP Research & Development2026-10-063.5K shat $61.38 | Sale10b5-1 plan | $214.8K |
| Robert I BlumPresident & CEO2026-09-287.5K shat $65.46 | Sale10b5-1 plan | $491K |
| Fady Ibraham MalikEVP Research & Development2026-09-223.5K shat $68.29 | Sale10b5-1 plan | $239K |
| Robert E LandryDirector2026-09-151K shat $72.13 | Sale10b5-1 plan | $72.1K |
| Robert I BlumPresident & CEO2026-09-1597.9K shat $69.33 | Sale10b5-1 plan | $6.8M |
| Robert I BlumPresident & CEO2026-09-147.5K shat $73.44 | Sale10b5-1 plan | $550.8K |
| Robert E LandryDirector2026-09-111K shat $74.66 | Sale10b5-1 plan | $74.7K |
| Fady Ibraham MalikEVP Research & Development2026-09-083.5K shat $75.46 | Sale10b5-1 plan | $264.1K |
| B Lynne ParshallDirector2026-09-015K shat $71.48 | Sale10b5-1 plan | $357.4K |
| Andrew CallosEVP, Chief Commercial Officer2026-08-3110K shat $70.24 | Sale10b5-1 plan | $702.4K |
| Robert I BlumPresident & CEO2026-08-317.5K shat $70.24 | Sale10b5-1 plan | $526.8K |
| Fady Ibraham MalikEVP Research & Development2026-08-183.5K shat $75.82 | Sale10b5-1 plan | $265.4K |
| Robert I BlumPresident & CEO2026-08-107.5K shat $76.76 | Sale10b5-1 plan | $575.7K |
| Andrew CallosEVP, Chief Commercial Officer2026-07-3014K shat $79.88 | Sale10b5-1 plan | $1.1M |
| Robert I BlumPresident & CEO2026-07-277.5K shat $80.87 | Sale10b5-1 plan | $606.5K |
| Fady Ibraham MalikEVP Research & Development2026-07-213.5K shat $80.59 | Sale10b5-1 plan | $282.1K |
| Robert I BlumPresident & CEO2026-07-1310 shat $82.02 | Sale10b5-1 plan | $820.2 |
| Robert I BlumPresident & CEO2026-07-137.5K shat $82.02 | Sale10b5-1 plan | $614.3K |
| Fady Ibraham MalikEVP Research & Development2026-07-073.5K shat $86.62 | Sale10b5-1 plan | $303.2K |
| Robert I BlumPresident & CEO2026-07-017.5K shat $84.92 | Sale10b5-1 plan | $636.9K |
| Andrew CallosEVP, Chief Commercial Officer2026-07-0115K shat $85.80 | Sale10b5-1 plan | $1.3M |
| Sung LeeEVP, Chief Financial Officer2026-07-011.1K shat $87.79 | Sale10b5-1 plan | $97.6K |
| Sung LeeEVP, Chief Financial Officer2026-06-293.1K shat $85.00 | Sale10b5-1 plan | $266.4K |
| Sung LeeEVP, Chief Financial Officer2026-06-2438.7K shat $82.30 | Sale10b5-1 plan | $3.2M |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on CYTK
Follow Cytokinetics Inc (CYTK) by email
New trades in Cytokinetics Inc (CYTK) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.